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1. OBJECTIVES
This paper presents preliminary findings from 15 case studies of consumers who each suspect they
may have experienced an adverse drug reaction (ADR). These case studies are part of a larger
qualitative study involving consumer/doctor decisions surrounding suspected adverse drug
reactions and prescribing, which is captured in Figure 1.
The key problem identified from our preliminary background work is that there appear to be
gaps in our knowledge about the decision environment surrounding suspected ADRs. The key gaps
identified in the preliminary work included the following:
• each of the groups interviewed (for details refer to Section 3.1 of this paper) involved in the
detection and management of ADRs had a different focus, indicating that there are multiple
groups of people involved, each with different data requirements,
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• the single consumer study indicated that ADR decisions may not purely be medical decisions
and others, including the consumer, may be involved in making decisions surrounding ADRs,
and finally, 
• a longitudinal perspective of an ADR, which includes the consumer view and multiple
components of the medical history, may provide information that is not available from any
single view.
The aim of this study is to gain further insights into the ADR decision environment to assist in
the development of decision support software tailored to this specific domain.
2. BACKGROUND
The Second National Report on Patient Safety: Improving Medication Safety by the Safety and
Quality Council of Australia (Roughead and Semple, 2002) describes adverse drug reactions as a
particular type of adverse drug event which includes side effects associated with medications.
Roughead and Semple (2002) reported that in Australia, between 1999 and 2000, 2–3% of total
Australian hospital admissions may have been associated with medications. This equates to about
140,000 of the total 5.9 million hospital admissions across Australia. 
Pirmohamed et al (1998) from the University of Liverpool, state that 5% of all hospital
admissions are caused by ADRs, and 10–20% of all hospital inpatients experience ADRs. They also
state that ADRs are responsible for the death of 0.1% of medical and 0.01% of surgical inpatients.
“To Err is Human. Building a Safer Health System” (Kohn, Corrigan and Donaldson, 1999)
provides incidence figures which have been quoted extensively as a rationale for continuing
research and development within this field. They state that the number of Americans to die each
year from medical error is somewhere between 44000–98000 reflecting 2.9–3.7% of hospital-
isations. These figures refer to adverse events, a term which covers any accident that occurs in
medicine such as errors in surgical procedures, incorrect medical procedures and equipment
failure.
We use the World Health Organisation (WHO) definition of an ADR which is “a response to a
drug which is noxious, unintended, and which occurs at doses normally used or tested in man for
prophylaxis, diagnosis, or therapy of disease, or for modification of physiological function.” (WHO,
1972). We have defined a suspected ADR as a set of symptoms that have been associated with a
therapeutic medication by either the consumer or treating clinician, but have not been verified by
the Australian Adverse Drug Reaction Advisory Committee (ADRAC).
ADRs are known to occur for a number of reasons. They can be caused by the pharmacological
action of the drug, changes in drug properties, such as an error in the manufacturing of a drug, and
drug interactions. Reactions can also be caused by the effects they can have on individuals. These
individual consumers may have particular hypersensitivities, idiosyncratic absorption or metabolic
characteristics, or particular conditions that are contra indicatory to particular drugs. Two of the key
reaction types are Type A and Type B reactions. Type A reactions are common, and dose related.
They are accounted for by a drug’s known pharmacological properties, (Kalachnick, 1999). Type B
reactions are uncommon and independent of a drug’s known pharmacological properties. They are
considered the most serious and are potentially life threatening, (Kalachnick, 1999).
Edwards and Aronson (2000) expand these categories including:
Type C, dose related and time related. Uncommon and related to the cumulative dose, 
Type D, delayed. Uncommon, usually dose related and usually becomes apparent some time after
the use of the drug, 
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Type E, withdrawal. Uncommon, occurs soon after the withdrawal of the drug and 
Type F, unexpected failure of therapy. Common, dose related and often caused by drug interactions. 
Efforts to reduce the incidence of ADRs appear to fall into five major categories: 
• voluntary reporting surveillance systems around the world such as the Therapeutics Goods
Administration, ADRAC system in Australia (TGA, 2003a; Grant, Coulson and Wood, 2000;
Hartmann et al, 1999; Kubota, 1999; Orsini and Funk, 1995; Sutcliff, McMorran and
Morawiecka, 2000),
• the World Health Organisation (WHO) reporting system which collects data from over 60
countries around the world in an attempt to detect signals that are too weak for any individual
country to detect (Lindquist et al, 1999),
The above two systems detect ADRs and then report recently discovered ADRs back to the
prescribers to assist with prescribing decisions.
• desktop prescribing systems that have built in alerts (Medtech, 2003; Medical_Director, 2003), 
• medical guidelines available on the Internet. (Beliakov and Warren, 2001; Barnett, Famiglietti,
Kim, Hoffer and Feldman, 1998; Thomas, Dayton and Peter, 1999) and 
• hospital based early detection systems that use data such as lab results, pathology results and
medications to alert staff to a possible ADR in its early stages so that it can be detected quickly.
These systems have also been used to estimate the number of ADRs occurring in a particular
hospital setting. Some examples include Payne et al (2000), Raschke et al (1998), Caldwell
(2000), Bates, (2000).
The results of voluntary reporting, product information and alerts built into desktop prescribing
software and medical guidelines, all provide information to the prescriber about the specific drug
and the illness or disease. The hospital-based systems provide information about illness and disease,
and additional specific information about the consumer such as lab results, pathology results and
medications. 
There is a significant body of research addressing the role of consumer decision-making within
a medical context (Charavell et al, 2001; Bankhead, 1999; Scott and Lenert, 2000; Coulter,
Entwistle and Gilbert, 1999; Benson and Britten, 2002; FDA, 2003; Bruera et al, 2001; Mcvea,
Minier and Johnson Palensky, 2001). These papers predominantly address treatment decisions. Our
preliminary background studies indicate consumer decisions surrounding ADRs may be broader
than decisions concerning treatment options, and that with or without decision support consumers
may be making diagnostic decisions. In some countries, consumers report suspected ADRs to health
authorities (NAPRA, 2003; TGA, 2003b; Safety And Quality Council, 2003). Each of the other
decision support strategies mentioned above do not consider consumer decisions.
There are many additional sources of information that may be used by prescribers and
consumers that are not currently included in the systems listed above. We aim, within this study, to
learn more about these information sources, understand more about how people currently use the
information that is available, the nature of the decisions being made, who makes these decisions,
and the additional requirements people have that may be able to assist in the prevention, early
detection and management of suspected ADRs.
3. METHODS
Figure 1 shows the groups of data that have been collected within the study described in this paper.
The shaded sections indicate the data collection that has been completed. Data were collected using
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informal methods within the preliminary background studies. These data were used as background
investigations to the formal study, which used a modified grounded theory approach, described
further in this section. The first component of the data was collected as a part of a General Practice
Computing Group funded study, Adverse Drug Reactions Improved Decision Support (ADRIDS)
(O’Brien, 2001). The first component of the formal study, consumers with suspected ADRs, is the
key focus of this paper.
3.1 Preliminary (Background) studies 
For each group illustrated in Diagram 1, notes were taken and fed back to each group member for
verification, except for the initial consumer case study where the consumer wrote the notes. The
analysis of this preliminary data was informal. The data were reviewed and summarised. Key points
were highlighted that were then used as a basis for the development of the formal study.
3.2 Consumer study
Subjects
Consumers who believe they may have experienced an ADR within the past 12–18 months
answered either an advertisement that was placed in a local newspaper, or one placed to staff and
students at the University of Ballarat, via a research newsletter and via e-mail. 20 consumers
responded, 15 met the selection criteria and were interested in participating in the study. 
The 15 participants have the following characteristics:
• age range of 29 to 76, with the following breakdown. 
– 20% aged 21–40, 60% aged 41–60, 20% aged 61–80
Figure 1: Data collected for the larger study of Consumer/Doctor decision making surrounding adverse drug
reactions and prescribing.
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– 67% female, 33% male, 
– 40% from Ballarat University, 60% from the community,
The suspected ADRs experienced by the participants have the following characteristics:
• Level of certainty that symptoms were caused by an ADR – 7% low, 13% medium, 7%
moderately high, 73% high
• Level of severity of the suspected ADR – 13% minor, 53% moderate, 34% moderately severe
• Who diagnosed the suspected ADR – 26% consumer only, 22% collaborative decision
between doctor and consumer, 21% collaborative decision between consumer and family, 26%
doctor only.
• Level of consumer concern – 20% low, 13% medium, 67% high
• Type of medication – 100% prescription, 0% non-prescription, 0% complimentary.
• Number of medications – 53% single medication, 47% multiple medications 
These characteristics have been categorised by the principal researcher based on the descriptions
provided by the participants. These levels are from the consumer perspective.
Self selection of consumers
This is an exploratory study, with the aim of performing a detailed, in-depth qualitative analysis of
a small number of case studies that include multiple views. The self-selection process may have
resulted in a set of consumers with particular characteristics.
The principal researcher noticed that the consumer group appeared to be particularly analytical, as
several of the participants maintained detailed diaries over a number of years, and the majority used
logical processing to determine the likelihood that the medication taken caused the suspected reaction.
It is also possible that the consumers volunteered for the study because they were particularly
concerned, angry or frustrated by their suspected reaction. As described in the previous section, the
group did have a significant level of concern, with 67% displaying a high level of concern as
observed by the principal researcher. It is not known if this level of concern is due to a bias in the
sample, or whether it is representative of consumers who have experienced a suspected reaction to
a medication. 
Attempting to minimize the effects of self-selection is difficult for the following reasons:
• It is not practical to observe consumers in a medical practice and collect cases of ADRs, as the
incidence is sparse compared with the number of cases seen within a practice,
• In order to collect the data, consumer consent is required. Beginning with a self-selection
process ensures consumer consent is obtained, and privacy is maintained,
• Medical staff could be approached to put forward cases of consumers who may have
experienced ADRs. Issues raised by medical staff to this proposal included the following:
– Some consumers may not be aware they have experienced an ADR, 
– The medical staff and/or hospital would need to contact each of these people to see if they
are prepared to participate in the study maintaining strict confidentiality, until such time as
the consumer signs a consent form to release their details to the research team, which is time
consuming for medical staff who are already extremely busy, 
– Medical litigation may result from drawing attention to suspected ADRs, especially in light of
the fact that in the majority of cases it is not 100% certain the medication caused the reaction.
As a result of the complexities above, the research team decided to begin with consumers who
were self selected, even though the self-selection may result in bias, rather than choose not to study
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this domain. As stated previously, this study is exploratory in nature and qualitative. We have the
aim of locating themes and emerging theory, which may be explored for generalisability in a follow-
up quantitative study, although the sampling issues will remain.
Method of Data collection
Each consumer participant was asked to do the following: Participate in a single in-depth semi-
structured interview with the principal investigator, assist in completing a time line of events
surrounding the suspected ADR, and complete a consent form to provide the principal investigator
with permission to access medical records, and discuss their case with their treating clinician.
Analysis of the Data 
Each interview was transcribed and de-identified. The data were coded using Nvivo 2.0 as an
analysis tool and using a modified form of grounded theory described by Miles and Huberman
(1994). Grounded theory, described by Strauss and Corbin (1998) is a method of developing theory
that has been derived from real world data. A social constructionist epistemology underpins our
approach. Miles and Huberman (1994) state that their preferred method of generating codes is to
begin with a “start list” of codes which came from prior fieldwork, the conceptual framework,
research questions, hypotheses and the literature. Our “start list” came from the preliminary work
described in Section 4.1, the literature and the research questions. This list evolved as cases were
analysed, allowing the data to expand and develop the code set.
4. RESULTS 
4.1 Preliminary background Studies 
The preliminary background studies highlighted key points that influenced the direction of the
formal study. Details can be found in O’Brien (2001). Below are the key points that were high-
lighted from each of the initial data gathering phases. 
GP Forums 
The perception of the group was that: 
• ADRs occur infrequently within a community setting,
• the number of medications on the market is increasing. As a result, updating their knowledge
about potential ADRs is also increasingly difficult,
• a computer program that sits in the background of their prescribing software would be useful.
Because their perception is that ADRs occur infrequently, they believe it is a high priority to
prevent them when possible, but a low priority regarding the time spent on ADR prevention
compared with the other demands within their workload. 
TGA discussions 
The members of the TGA ADR team reported that:
• their primary role is to discover previously undocumented ADRs, to document them and alert
the public as to their existence,
• background information about how the TGA ADR team operates was recorded. Detailed infor-
mation about this has been documented in O’Brien (2001),
• a key element in identifying an ADR is to differentially diagnose between an ADR, the
presenting disease, or a newly presenting disease. Generally this can be done with only a limited
level of certainty, particularly if the ADR is one that has not been previously documented. Often
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it is not possible to do this differential diagnosis at the time the ADR occurs, but new ADRs can
be discovered if prescribers report suspected ADRs. If there are enough reports from within
Australia or around the world to produce a signal, ADRAC can be more certain that there is a
relationship between a drug or group of drugs and a symptom or set of symptoms.
Consumer
This single case study highlighted the following:
• Medical data for this consumer was stored in many locations. The consumer was the only person
who knew where the complete medical history was located, and she was too ill to alert medical
staff. She had experienced similar symptoms 10 years earlier, but had only limited information
about that suspected reaction,
• The consumer made decisions that may have impacted on the outcome of the ADR. These
decisions included, when to seek medical assistance, who to seek medical assistance from and
what information from her past medical history was relevant to relay to the doctor,
• Having experienced a life-threatening ADR, she is highly motivated to prevent future ADRs.
Pharmacist
The pharmacist provided insight into the ADR reporting practices within a single Melbourne
hospital.
He also highlighted the following:
• If a person has experienced an ADR, ensuring the person has enough knowledge to prevent a
second exposure to that medication was a high priority,
• Accurate diagnosis is essential, although often extremely difficult. He stated that blaming a drug
for an ADR means the person does not have access to that form of drug therapy in the future.
Not detecting the drug, results in an increased risk of the person being re-exposed to the same
drug a second time.
Summary of Preliminary (Background) Study Results
The results of the background study highlighted specific issues to explore in detail in the formal
study (below). In particular, the complex nature of ADRs was highlighted. The number of drugs on
the market and drug complexity is increasing. ADRs are often not diagnosed definitively, but are
suspected to a particular level of certainty. There are many views of an ADR – emphasis on
minimizing risk of experiencing an ADR, early detection, prevention of re-exposure to a medication
that has previously caused a reaction and the impact of implicating a drug. Another aspect
highlighted in the background study is the role of the consumer. This consumer was highly
motivated to prevent further ADRs due to the severe nature of the ADR. She made a variety of
decisions, not just treatment decisions and she held key information needed for the diagnosis of the
ADR. The final and most significant aspect highlighted is that ADRs appear to cross multiple
decision makers, information is in multiple locations, and the interrelations between these factors is
not clear. The Formal study described below aims to explore these factors in detail. The formal
study includes 15 additional consumer case studies, discussed below.
4.2 Consumer study 
Following the background studies, the larger study includes 15 consumer interviews, which have
generated a large quantity of data, resulting in a large number of factors that may be of significance.
The suspected ADRs for the 15 cases have been summarised in Table 1, below. Five key points will
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be discussed in this paper: the perception of the severity of suspected ADRs, multiple decision
makers, types of decisions made by consumers throughout a suspected ADR, knowledge sources
used by consumers, impact of a suspected ADR linked to consumer understanding of the source of
the symptoms.
It should be noted that the suspected reactions below are from a consumer perspective only, and
have not at this stage of the research process been verified by a Medical Officer.
Perception of the severity of suspected ADRs 
Although the suspected reactions of the 15 consumers reported in Table 1 (below), are not life
threatening and did not cause death or permanent physical injury, each consumer found the
suspected reaction distressing. Column 7 in Table 1 shows the impact of the suspected reaction on
each of the consumers, in most cases, using the consumer’s own terminology. The impact appeared
to fall into three key categories; impact of the suspected reaction, impact that continued after the
initial symptoms had subsided, and impact on others as a consequence of the suspected reaction.
Below are some examples.
The first two quotes, below, indicate the impact on the consumer whilst experiencing the
suspected reaction.
“I got home but I had to go to work for half an hour so my husband was going to drive me
there because I really felt like I couldn’t drive, I was feeling really miserable.” (C02)
“I said (to GP) I’m miserable, I said my legs, I said I’ve got pain, I’ve got this restless legs,
I’ve got this thigh pain around here and stuff like that and I said I’m miserable you know I
really am. Is this the way life’s supposed to be” (C17)
C02 had 8 weeks of illness. C17 indicated that the symptoms had persisted for three years
progressively getting worse.
Consumer Symptoms Drug Level of Source of knowledge Who Impact
Code Certainty used by consumer diagnosed
and doctor as per-
ceived by consumer
C02 Severe flu Tegretol High GP consulted Doctor “I really felt like
style specialist I couldn’t drive, 
illness I was feeling
really miserable.”
“he said (GP) 
“you are 
seriously ill”” 
C04 Itchy in Tramadol High Internet, Doctor Concerned and
absence of Hydro- observation and confused not  
rash  chloride asking the doctor knowing the cause 
C05 Grand Mal Generic Consumer Elimination of Consumer “The impact for 
first for brand of High, other possible and doctor me personally
20 years. sodium Doctor, factors was huge”
valproate Low      
C06 Convulsions Panadeine Medium Advice from doctor Doctor “I won’t take it  
Forte     again, just in case.” 
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C07 Aches in Tamoxifen High Consumer’s reflection Consumer “I just felt I was
legs, nausea and specialist’s suspected getting weaker and
medical knowledge medication – sicker and I was
Doctor angry by this stage
confirmed too…. I felt that I
was bit fobbed off” 
C08 Slow Inderal Medium Observation and Consumer “I don’t want to be 
recovery prior knowledge of and GP prescribed drugs
from medication suspected again if it’s not
epidural necessary.” 
C09 Bells Palsy Zyban Mod High Observation Consumer “I was nearly in 
tears, I didn’t know
what was wrong” 
C10 Vomiting Efexor High Symptoms Consumer “Nobody on earth 
after second immediately could talk me into 
dose for 2 following taking trying it again.” 
weeks  the drug. 
C11 Drug Hydral- High Observation, Internet Consumer, “I was just in
induced azine confirmed agony”  
lupus by doctor   
C12 Felt ill Panadeine High Observation over Consumer “It delayed my 
enough to Forte several uses over and wife return to work” 
miss work.    time     
C13 Photo- Celebrex High Observation and the Consumer “The impact was
sensitivity – Internet major. For the
pustule rash       period of the 
reaction I was
miserable.” 
C14 Photo- Vioxx Low Observation and Consumer, Searching for an,
sensitivity – information from wife and explanation for the 
itchy rash    friends   daughter.   symptoms for 18 
months. 
C15 Double Maxolon High Doctor referred to Doctor “I’m terrified of 
vision ADR reference having any more 
material.    surgery absolutely 
terrified” (after a 
series of unpredic
table reactions to 
drugs) 
C16 Induced Sabril High Timing of medication Consumer “was terrifying”   
severe with suspected and husband “It did shatter me
seizure – reaction. psychologically”
similar to 
psychotic 
episode       
C17 Restless Lipitor High Observation by the  Consumer “I’m miserable…. 
legs, unwell, consumer and his [its] the decrease  
pain in legs   wife, own medical in the quality of  
knowledge, Internet. life”  
Table 1: Detecting suspected ADRs from a consumer's perspective
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The following case indicates how a suspected reaction may have an initial impact, but then has
a longer-term impact such as increased sensitivity to the sun, impacting on lifestyle for a number of
years.
“I would say the impact was major. For the period of the reaction I was miserable. I needed
to miss work because of it. I felt sick with it as well. So from that point of view that episode
was major. It impacted on my holiday. And then I had had subsequent episodes with Ultra
violet light exposure, since then. So to me, that’s a major impact, because I enjoy the sun, I
enjoy being outside, and I enjoy outdoor activities. It means that I have to be extremely
careful with exposure to the sun. Wear sunscreen, cover up. That sort of thing.” (C13)
A secondary impact for C10 was that he was the primary carer for his wife who had a
progressive disease. The impact, included the immediate illness he experienced, but the secondary
impact of being unable to care for his wife for this period of time. When asked about this impact,
he indicated that they were able to call on the support of family and home carers, however, he said
“we battled on I guess, sometimes we didn’t get much for tea if anything. Sometimes we did.” 
Multiple decision-makers 
Within these 15 cases, the people involved in decision-making (either making decisions or provid-
ing observational input into the decision-making) included, the prescriber who was either the GP or
a specialist, the consumer, members of the consumer’s family and the consumer’s friends. Table 1,
column 6 shows that from the consumer’s perspective, the consumer involved in suspecting the
symptoms to be an ADR in 11 of the 15 cases and in 7 of the 15 cases describe this decision as
collaborative. The collaboration is with a family member in four of these cases and with the doctor
in three cases.
As can be seen from the data presented in Table 1, in the majority of cases, from the consumer’s
perspective, they were significantly involved in the diagnostic decision of whether or not to suspect
a drug of causing a reaction.
Types of decisions made by consumers throughout a suspected ADR
Table 1 explores the decision type of “suspecting a drug to have caused an adverse drug reaction”.
Other decisions made by the consumers within these 15 cases are described in Table 2.
As can be seen from Table 1, consumers are involved in a wide range of decisions surrounding
suspected ADRs. As indicated in the background section to this paper, the majority of decision
support is provided to the prescriber, and the majority of decision support systems that involve
consumers are focused on treatment decisions. The results of this study indicate that the decision
types made by consumers are significantly broader than the current decision support focus.
Knowledge sources used, and usages of knowledge sources by the consumers
The sources of knowledge/information used by the 15 consumers included: 
• the product information sheet (when available), 
• observations of own symptoms, 
• personal diaries, 
• knowledge of when medications were commenced and/or ceased,
• dosage, and awareness time required for medication to reach therapeutic level,
• logical processing of events and symptoms,
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• consumer drug information sheet from the pharmacist, 
• the Internet to search for current drug or class of drugs or an alternative drug, 
• information about a specific condition and progression of the condition, 
• case studies similar to own, 
• advice from doctor, 
• advice from a family member, 
• own knowledge of medicines from past experience, 
• family members’ recollection of events and observations of symptoms, 
• family friends and 
• the pharmacist. 
Decision Type Description 
Seeking information Who to seek information from; Doctor, pharmacist, naturopath, friend,
family 
When to seek information. Immediately, symptoms severe? 
Where to seek information – internet, person, media, drug information 
Diagnostic decisions Decision to suspect a drug of causing a reaction 
Decision to suspect a class of drugs of causing a reaction 
When given a diagnosis, whether to accept the diagnosis 
Treatment decisions Which medication to take – prescription, non prescription or
complimentary 
Decision to request a specific drug from a medical practitioner 
Decision between multiple suitable drugs 
Decision to take medication prescribed for self, for a previous illness
Whether to take prescribed medication 
When to begin or cease a drug 
Frequency of drug 
Whether to follow recommendations by doctor or product information
Choosing a medication prescribed for a family member or friend 
Information sharing Whether to report a suspected reaction to a medication practitioner
Whether to report new symptoms 
Which information to share 
Whether to request specific information about a drug 
Determine the priority for treatment 
Inform medical practitioner of ceasing a medication 
Inform a medical practitioner of non-compliance – eg higher dose than
recommended. 
Side effects/reactions Whether to accept a side effect because of the benefits of the
medication. 
When to report a suspected reaction to a medical practitioner
Table 2: Decisions made by consumers during a suspected ADR
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Sources of knowledge used by the doctor as perceived by the consumer included feedback from
specialists and accessing reference materials about known ADRs. 
As can be seen by the list of information sources, above, the consumer group accessed
information from a variety of sources, only one being from a medical practitioner. 
More data will be available about information and knowledge used once data has been collected
from the remainder of the treating clinicians, the GP group and the TGA ADR team.
Impact linked to expectations 
In a few cases the consumers were accepting of uncomfortable symptoms that they expected but
were distressed when they did not know the cause of symptoms. One example was the consumer
who suspected Zyban of causing Bell’s Palsy. The quote below indicates an acceptance of some
symptoms that were severe enough to stay home from work.
“Headaches are one of the side effects of Zyban as is throwing up.” “they were enough to
prevent me from working, lying in bed in darkness.” “The doctor said no, no, no that’s alright
it’s just side effects so I continued.” (C09)
The following two quotes indicate the stress associated with not knowing the cause of the
symptoms of the suspected ADR.
“I think that if I’d known that that was possibly a side effect it would have been less
traumatic because it was really quite stressful not knowing why.” (C04)
“The double vision was distressing, because I’d never had it before, and didn’t know why I
had it.”(C15)
The consumers were asked if they would do anything differently or would have like the medical
staff to do anything differently if they were to face the same circumstances again, using the
advantage of hindsight. The majority of the participants indicated they would have liked to have
been warned that the medication they were taking may result in a reaction. Some also indicated that
some idea of when to seek medical advice would also have been useful.
5. DISCUSSION 
The results of this paper suggest that there are multiple decision-makers involved in ADR decisions.
If, as indicated here, consumers are making decisions with or without support, it seems reasonable to
suggest that decision support be tailored to accommodate different and collaborative perspectives.
Also, decision-makers working together more explicitly may assist in the prevention, and in particular
the early detection and management of suspected ADRs. To date decision support for ADRs has been
directed towards prescribers as described in the background section (Section 2) of this paper.
Benson and Britten’s (2002) study on consumer decisions surrounding hypertensives, explore
the factors consumers use when weighing up treatment decisions, and found that the reasons are
broader than those relating to the pharmacology of the drug, and that pre-conceived ideas about
medicines can have an impact on decision making. Benson and Britten (2002) support the notion of
shared decision making concluding that “doctors who want their patients to make well informed
choices about antihypertensives and to reach concordant decisions about prescribing should explore
how individuals strike this balance to personalise discussion of drug use”.
The decision types made by consumers were significantly more extensive than treatment
decisions. To date decision support for consumers has focused primarily on treatment decisions,
with little or no information found by the authors exploring the role of consumers in diagnostic
decisions. This study suggests the need to broaden the decision types used in decision support. 
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ADRs that are not life threatening or causing permanent physical illness were, in this study,
significant to the consumer. In the preliminary work, the consumer case study included a consumer
who was highly motivated to prevent further ADRs when the ADR was life threatening. The
consumers in this study, who suspect they experience ADRs, also had high motivation to prevent
further ADRS. This observation provides a rationale for providing resources to aid in the manage-
ment of this class of ADRs.
Information that relates to ADRs is held in many locations by many decision-makers, and
includes pharmacology of drugs and the likely physiological impact of a reaction, but also
information held by the consumer such as personal experiences, observations of family and friends
and knowledge of their own body. The combining of that partial knowledge may assist with the
prevention, early detection and management of ADRs.
Coulter et al (1999) state “patients cannot express informed preferences unless they are given
sufficient and appropriate information, including detailed explanation about their condition, likely
outcomes with and without treatment.” This statement is true of medical information, but as
expressed by Benson and Britten (2002), consumer decisions involve information that is broader
than medical information, implying that providing access to consumers about medical information,
although important, is not the entire solution.
Finally, if awareness that a medication may result in an unwanted reaction decreases the severity
of the experience of an ADR, as indicated by some of the cases within this study, perhaps increased
awareness is important. This issue is complex. It is difficult to predict which person may react to
which medication. There is also a risk of information overload, and increased anxiety to consumers
if they are informed of a severe, yet unlikely reaction. It is possible for a consumer to experience
the nocebo effect, i.e. “ a harmless substance that when taken by a patient is associated with harmful
effects due to negative expectations or the psychological condition of the patient”. The results,
however, indicate that there are also some benefits to having prior warning, which may be useful
when considering the development of decision support in this field.
6. CONCLUSION
Decision support to assist with ADRs has, to date, primarily focused on providing in time
information to prescribers about factors that pertain to the consumer and the medications they are
taking to prevent, detect and manage ADRs. Decision support that includes consumers usually
targets treatment decisions. As can be seen from this work, multiple decision makers were involved
in ADR decisions, and consumer decision types were significantly broader than treatment decisions.
The consumers in the study used a variety of sources of information to make their decisions, seeking
advice from a medical practitioner being only one information source. This study indicates that
decision support aimed only at prescribers, will result in a system that only partially meets the needs
of the ADR decision domain, and is likely to be less effective that one that attempts to incorporate
the requirements of consumers also, as active decision makers.
Two additional factors were highlighted from this study. Firstly that the less severe ADRs, in
medical terms, were significant to the consumers experiencing them, indicating a need to address
this subgroup of ADRs, and also, awareness that a medication may cause specific ADRs, although
difficult to predict, may assist in the reduction of the experience of an ADR. 
It is planned that future research will look at the implications of this research on decision support
technology within an ADR decision environment. As this study is exploratory in nature using a
qualitative methodology, allowing previously unknown issues to be raised, follow up quantitative
studies may be required in order to generalise these results to the general population.
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